ABBVIE Aktie

 

— Up to eight winners to receive up to $500,000 each in pre-seed funding, incubator space, equity for discovery services, and expert mentorship— — New sponsors AbbVie, TIAP, Connecticut Innovations, CCRM, and Norton Rose Fulbright join existing partners Mission BioCapital, Ono Venture......

ABBV's oncology lineup faces a 2026 sales dip despite rising contributions from newer drugs, as pricing pressure on Imbruvica weighs on growth....

First-Time Users Can Claim $400 Off Their First Body Contouring Treatment.*† IRVINE, Calif., March 31, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its fourth annual CoolMonth, featuring exclusive offers on CoolSculpting®, the treatment doctors use......

NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be......

AbbVie (ABBV) concluded the recent trading session at $213.12, signifying a +1.78% move from its prior day's close....

Product Development Highlights: Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic stress disorder (PTSD) Identified neuroplastogen candidates with potential to promote brain-derived neurotrophic factor (BDNF) signaling, an established therapeutic target for neurodegenerative disease Corporate and Business Development Highlights: Announced the withdrawal of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric's issued U.S. Patent No. 12,138,276, which appears relevant to the bretisilocin (GM-2505) molecule acquired by AbbVie, Inc. Continued to strengthen Enveric's expansive IP portfolio directed to molecules intended to provide non-hallucinogenic treatment options. Multiple patents and notices of allowance were issued for its EVM301 Series, including a novel family of molecules including melatonin receptor-targeting compounds...

Data highlights efficacy and safety of risankizumab in psoriatic disease, including high impact areas in psoriasis and long-term treatment of psoriatic arthritis Data includes real-world evidence of minimal disease activity and clinical long-term safety outcomes of upadacitinib in atopic......

The stock has averaged annual gains of 16.2% over the past decade, and it sports a generous dividend yield, too....

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store....

Partnership expands "Striking Out Cancer" campaign beginning on Opening Day AbbVie named Official Pharmaceutical Partner of Major League Baseball (MLB), expanding Striking Out Cancer league-wide starting on Opening Day Each strikeout will trigger a donation from AbbVie to support Stand Up......

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation....

AbbVie (ABBV) reached $206.23 at the closing of the latest trading day, reflecting a -1.01% change compared to its last close....

AbbVie stock sinks 5% as J&J's newly approved Icotyde raises competitive concerns for blockbuster Skyrizi in the fast-growing IL-23 market....

Shares of AbbVie Inc. (NASDAQ: ABBV) are moving lower Wednesday. The stock appears to be trending down after a competitor announced significant progress made on a treatment for plaque psoriasis. Importance Rank:  1 read more...

AbbVie slips below its 50-day SMA, signaling short-term weakness, but strong drug growth and a solid long-term uptrend may keep investors holding or buying dips...

AbbVie (ABBV) closed the most recent trading day at $219.68, moving 2.52% from the previous trading session....

The bipolar depression market is anticipated to increase during the forecast period (2026–2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie),......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Die Pharma-Konzerne Eli Lilly und Novo Nordisk dominieren den Markt für Appetitzügler. Das enorme Potenzial hat inzwischen auch andere Pharma-Konzerne auf den Plan gerufen, die dem Duo mittel- bis langfristig Marktanteile streitig machen wollen. Dazu gehört auch AbbVie....

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....